BACKGROUND: Chondrolysis initiated by postoperative, intra-articular pain pumps has recently been described by multiple institutions. PURPOSE: To evaluate the in vitro chondrotoxicity of anesthetic formulations commonly used in pain pumps. STUDY DESIGN: Controlled laboratory study. METHODS: Freshly isolated human articular chondrocytes were cultured for 24-, 48-, and 72-hour trials in a custom bioreactor that mimics the metabolism of synovial fluid. Chondrocytes were perfused in Dulbecco's Modified Eagle's Medium 10% fetal bovine serum and one of the following medications: 1% lidocaine, 1% lidocaine with epinephrine, 0.25% bupivacaine, 0.25% bupivacaine with epinephrine, 0.5% bupivacaine, or 0.5% bupivacaine with epinephrine. Static and perfusion cultures with growth media were used as controls. All experiments were run in duplicate. Live/dead staining was performed, and the ratio of dead:live cells was assessed by fluorescent microscopy and histomorphometry. RESULTS: Significantly more chondrocyte necrosis was found in all cultures with medications containing epinephrine (P < .05) at all time points. Similar necrosis rates were exhibited in 0.25% and 0.5% bupivacaine compared with controls at 24 and 48 hours. However, 0.5% bupivacaine produced significantly more cell death at 72 hours. Similar necrosis rates were exhibited with 1% lidocaine compared to controls at 24 hours. CONCLUSION: In this in vitro model, 0.25% and 0.5% bupivacaine caused minimal chondrocyte necrosis when used in pain pumps for a maximum of 48 hours. All anesthetics containing epinephrine (pH <or=4) were chondrotoxic and cannot be advocated for pain pump use. The use of 0.5% bupivacaine for greater than 48 hours is not recommended. CLINICAL RELEVANCE: The results of this study may help improve the safety of intra-articular pain pump use by examining the effects of local anesthetics on chondrocyte viability.
BACKGROUND: Chondrolysis initiated by postoperative, intra-articular pain pumps has recently been described by multiple institutions. PURPOSE: To evaluate the in vitro chondrotoxicity of anesthetic formulations commonly used in pain pumps. STUDY DESIGN: Controlled laboratory study. METHODS: Freshly isolated human articular chondrocytes were cultured for 24-, 48-, and 72-hour trials in a custom bioreactor that mimics the metabolism of synovial fluid. Chondrocytes were perfused in Dulbecco's Modified Eagle's Medium 10% fetal bovine serum and one of the following medications: 1% lidocaine, 1% lidocaine with epinephrine, 0.25% bupivacaine, 0.25% bupivacaine with epinephrine, 0.5% bupivacaine, or 0.5% bupivacaine with epinephrine. Static and perfusion cultures with growth media were used as controls. All experiments were run in duplicate. Live/dead staining was performed, and the ratio of dead:live cells was assessed by fluorescent microscopy and histomorphometry. RESULTS: Significantly more chondrocyte necrosis was found in all cultures with medications containing epinephrine (P < .05) at all time points. Similar necrosis rates were exhibited in 0.25% and 0.5% bupivacaine compared with controls at 24 and 48 hours. However, 0.5% bupivacaine produced significantly more cell death at 72 hours. Similar necrosis rates were exhibited with 1% lidocaine compared to controls at 24 hours. CONCLUSION: In this in vitro model, 0.25% and 0.5% bupivacaine caused minimal chondrocyte necrosis when used in pain pumps for a maximum of 48 hours. All anesthetics containing epinephrine (pH <or=4) were chondrotoxic and cannot be advocated for pain pump use. The use of 0.5% bupivacaine for greater than 48 hours is not recommended. CLINICAL RELEVANCE: The results of this study may help improve the safety of intra-articular pain pump use by examining the effects of local anesthetics on chondrocyte viability.
Authors: R Nelson Mead; Jessica Ryu; Sen Liu; Dongxia Ge; Justin Lucas; Felix H Savoie; Zongbing You Journal: Arthroscopy Date: 2011-12-14 Impact factor: 4.772
Authors: Sen Liu; Qing-Song Zhang; William Hester; Michael J O'Brien; Felix H Savoie; Zongbing You Journal: Am J Sports Med Date: 2012-03-16 Impact factor: 6.202
Authors: Nicole A Friel; Vincent M Wang; Mark A Slabaugh; FanChia Wang; Susan Chubinskaya; Brian J Cole Journal: J Shoulder Elbow Surg Date: 2012-07-20 Impact factor: 3.019
Authors: Hillary J Braun; Nathaniel Wilcox-Fogel; Hyeon Joo Kim; Michael A Pouliot; Alex H S Harris; Jason L Dragoo Journal: Knee Surg Sports Traumatol Arthrosc Date: 2011-10-29 Impact factor: 4.342